Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, et al.
Pharmacological Research (2024) Vol. 202, pp. 107123-107123
Open Access | Times Cited: 18

Showing 18 citing articles:

Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities
Bitian Zhang, Ping‐Chung Leung, William C. Cho, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy
Zhonglei Wang, Wenjing Xu, Shizeng Lei, et al.
Colloids and Surfaces B Biointerfaces (2025) Vol. 250, pp. 114557-114557
Closed Access
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 470-470
Open Access
METTL3/IGF2BP2 Promotes the Malignant Progression of Esophageal Cancer by Activating the PIK3CA/AKT Pathway
Xinmeng Guo, Anqi Huang, Yuan Qi, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 4
Open Access
Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2042-2042
Open Access
Impact and reproducibility of in-house targeted next-generation sequencing biomarker testing in non-small cell lung cancer: an Italian multi-institutional experience
Ida Rapa, Francesca Bertola, Gaia Roversi, et al.
Journal of Molecular Diagnostics (2025)
Open Access
Comprehensive analysis of the potential mechanism of gansui in blocking non-small cell lung cancer progression
Xiaoxu Yang, Wenlan Li
Pharmaceutical Biology (2025) Vol. 63, Iss. 1, pp. 170-187
Open Access
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Thulo Molefi, Lloyd Mabonga, Rodney Hull, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 382-382
Open Access
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
P. Chavan, Ruchi Pandey, BHEEMANAGOUDA O. PATIL, et al.
European Journal of Pharmacology (2025), pp. 177494-177494
Closed Access
Combining network pharmacology and transcriptomics to validate and explore the efficacy and mechanism of Huayu Wan in treating non-small cell lung cancer
Tangke Gao, Shaopu Hu, Min Jiang, et al.
Journal of Ethnopharmacology (2025), pp. 119724-119724
Open Access
Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review)
Carlos Henrique Diniz, Tiago Henrique, Ana Carolina Buzzo Stefanini, et al.
Oncology Reports (2024) Vol. 51, Iss. 6
Open Access | Times Cited: 3
Regulation, Functional Impact, and Therapeutic Targeting of APOBEC3A in Cancer
Ajinkya S. Kawale, Lee Zou
DNA repair (2024) Vol. 141, pp. 103734-103734
Closed Access | Times Cited: 2
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access | Times Cited: 1
Design, Synthesis, and Pharmacological Evaluation of Triazine-based PI3K/mTOR Inhibitors for the Potential Treatment of Non-Small Cell Lung Cancer
Ming Zeng, Ying-xuan Hu, Lan Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117200-117200
Closed Access | Times Cited: 1
39. UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ CÓ ĐỒNG THỜI ĐỘT BIẾN GEN EGFR VÀ PIK3CA: KẾT QUẢ ĐIỀU TRỊ BƯỚC ĐẦU TẠI BỆNH VIỆN PHỔI TRUNG ƯƠNG GIAI ĐOẠN 2022-2024
Lê Tú Linh, Đinh Văn Lượng, Đặng Duy Hiếu, et al.
Tạp chí Y học Cộng đồng (2024) Vol. 65, Iss. CD3
Open Access
Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines
Tharsagini Nanthaprakash, Campbell W. Gourlay, Ina Oehme, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
New generation sequencing and genomic mapping: towards precision molecular diagnosis of lung cancer in Morocco
Ouafaa Morjani, Noura Mounaji, Meriem Ghaouti, et al.
Pan African Medical Journal (2024) Vol. 49
Open Access
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
Kai Sun, Peng Wang
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top